Real-World Evidence: The Case of Peru

Real-World Evidence The Case of Peru

Causality Between Ivermectin and COVID-19 Infection Fatality Rate

Introduction

Much has been said much about Peru and its use of Ivermectin as a treatment for the coronavirus. The South American country has been a point of reference regarding its use. The Peruvian government approved the use of Ivermectin by decree on May 8. Despite having received several requests to suspend it in September, Pilar Mazzetti, the new Minister of Health, ratified it. These measures have aroused much criticism among the scientific community. They do not understand why they continue to distribute the antiparasitic drug without having a randomized blind study to prove its effectiveness and overlook that the total death toll from COVID-19 in Peru is one of the world's highest.

Turning away from opinions and moving on to facts, it is necessary to verify whether the ivermectin interventions have matched with variations in the virus's mortality and lethality. And if they match a decrease in the number of new cases, a younger infected population, a substantial reduction in the most vulnerable people, or other factors could explain the variations.

This analysis evaluated the impact of ivermectin ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee